Admin
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Admin | Published : August 18, 2012 9:46 AM IST
A new bio-therapeutic clot-buster drug may soon enter phase one of human clinical trials. After approval by the Drug Controller General of India (DCGI) the durg is all set to be tested on humans. The drug, earlier licensed from a US-based firm, has been designed by Chandigarh-based Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (CSIR-IMTECH).
"Clot-specific streptokinase (CSSK), a pioneering bio-therapeutic clot buster drug from the CSIR-IMTECH has been cleared Thursday by the office of the DCGI for Phase-One Human Clinical trials," the statement from CSIR said. The drug is helpful in saving lives of patients suffering heart attacks; it can also reduce the risk of internal bleeding, associated with the use of clot busters. The drug has recently been successfully tried in test animals including monkeys. Its design and process development and scale-up was achieved by a team led by CSIR-IMTECH Director Girish Sahni.
Source: IANS
